A140410 Stock Overview
Mezzion Pharma Co.,Ltd. engages in the development, manufacturing, and sale of pharmaceutical products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mezzion Pharma Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩37,500.00 |
| 52 Week High | ₩54,100.00 |
| 52 Week Low | ₩24,200.00 |
| Beta | 0.78 |
| 1 Month Change | -4.21% |
| 3 Month Change | 8.38% |
| 1 Year Change | 50.30% |
| 3 Year Change | -31.94% |
| 5 Year Change | -2.43% |
| Change since IPO | 278.15% |
Recent News & Updates
Shareholder Returns
| A140410 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.2% | -0.2% | 1.0% |
| 1Y | 50.3% | 9.5% | 8.7% |
Return vs Industry: A140410 exceeded the KR Pharmaceuticals industry which returned 9.5% over the past year.
Return vs Market: A140410 exceeded the KR Market which returned 8.7% over the past year.
Price Volatility
| A140410 volatility | |
|---|---|
| A140410 Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A140410's share price has been volatile over the past 3 months.
Volatility Over Time: A140410's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 45 | Dean Park | www.mezzion.co.kr |
Mezzion Pharma Co.,Ltd. engages in the development, manufacturing, and sale of pharmaceutical products in South Korea. It is developing udenafil, a PDE5 protein for the treatment of erectile dysfunction, benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, and single heart failure diseases.
Mezzion Pharma Co.,Ltd. Fundamentals Summary
| A140410 fundamental statistics | |
|---|---|
| Market cap | ₩1.11t |
| Earnings (TTM) | -₩12.73b |
| Revenue (TTM) | ₩31.72b |
35.1x
P/S Ratio-87.5x
P/E RatioIs A140410 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A140410 income statement (TTM) | |
|---|---|
| Revenue | ₩31.72b |
| Cost of Revenue | ₩27.84b |
| Gross Profit | ₩3.88b |
| Other Expenses | ₩16.61b |
| Earnings | -₩12.73b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -428.57 |
| Gross Margin | 12.25% |
| Net Profit Margin | -40.13% |
| Debt/Equity Ratio | 0.8% |
How did A140410 perform over the long term?
See historical performance and comparison